Active substance
Phenazopyridine
- SFDA 1
- Health Canada 1
- US price lines 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| URISEPT 100MG TABS | 100 mg | Tablet · Oral use | 20 Blister | SAR 5.35 | NCE · OTC | KAHIRA EYGEPT | Withdrawn by regulatory authority · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PYRIDIUM | 00476714 | 100 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PHENAZOPYRIDINE 100 MG TAB | $0.154 | per EA | 23 Sep 2026 |
| US NADAC | PHENAZOPYRIDINE 200 MG TAB | $0.17596 | per EA | 23 Sep 2026 |
| US NADAC | PHENAZOPYRIDINE HCL 95 MG TAB | $0.13162 | per EA | 23 Sep 2026 |
| US NADAC | PYRIDIUM 200 MG TABLET | $5.463 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.